8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2010

STRYKER CORPORATION

(Exact name of registrant as specified in its charter)

Michigan	0-9165	38-1239739
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2825 Airview Boulevard, Kalamazoo, Michigan	49002
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 269.385.2600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 8 - OTHER EVENTS

ITEM 8.01 OTHER EVENTS.

The Company issued a press release on March 23, 2010 announcing the resolution of FDA warning letter related to the Company’s Mahwah, New Jersey manufacturing facility. A copy of this press release is attached hereto as Exhibit 99.1.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

The following exhibit is included with this Report:

Exhibit
99.1	Press release announcing the resolution of FDA warning letter related to the Company’s Mahwah, New Jersey manufacturing facility.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STRYKER CORPORATION
	(Registrant)
March 25, 2010	/s/    CURT R. HARTMAN
Date	Curt R. Hartman
	Vice President and Chief Financial Officer

2

EX-99.1

Exhibit 99.1

2825 Airview Boulevard Kalamazoo, MI 49002
	PRESS RELEASE

NUMBER:	2010-09
DATE:	March 23, 2010
CONTACT:	Katherine A. Owen
	Vice President, Strategy and Investor Relations
	269-385-2600

STRYKER ANNOUNCES RESOLUTION OF FDA WARNING LETTER

RELATED TO ITS MAHWAH, NEW JERSEY MANUFACTURING FACILITY

Kalamazoo, Michigan – March 23, 2010 – Stryker Corporation (NYSE:SYK) today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the actions undertaken by the Company to address the issues raised in a 2007 Warning Letter are sufficient.

The Company received the Warning Letter from FDA regarding compliance with certain quality system requirements at its reconstructive implant manufacturing facility in Mahwah, New Jersey in 2007. Following FDA re-inspection in 2009 and additional corrective actions, the Company has been informed that issues raised have been adequately addressed and no further formal corrective actions are required.

“The resolution of the Mahwah, New Jersey Warning Letter is another important step in demonstrating our firm commitment to significantly transforming our quality systems throughout our organization” said Stephen P. MacMillan, Stryker’s Chairman, President and Chief Executive Officer. “The investments we have made, and will continue to make, are resulting in solid progress toward our goals.”

About Stryker

Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

Contacts

For investor relations inquiries, please contact:

Katherine Owen, Vice President, Strategy and Investor Relations of Stryker Corporation,

269-385-2600

For media inquiries please contact:

Gabrielle Zucker, Kwittken & Company, 646-747-7143 or stryker@kwitco.com